Microbot Medical® Welcomes Updated Occupational Protection Guidelines from Leading Medical Societies, Strengthening Commercial Position of LIBERTY®
Rhea-AI Summary
Microbot Medical (NASDAQ: MBOT) highlighted updated occupational protection guidelines from SIR and CIRSE on April 22, 2026, which address radiation exposure, ergonomic risks and pregnancy protections for interventional staff.
The company positioned its LIBERTY Endovascular Robotic System as a potential solution to reduce radiation exposure and musculoskeletal strain, noting endorsements from at least nine medical societies and an AMA policy adopted in late 2025.
Positive
- At least nine medical societies endorse updated occupational protection guidelines
- SIR and CIRSE issued joint guidelines addressing radiation and ergonomic risks (April 2026)
- AMA policy (late 2025) strengthens protections for providers facing occupational radiation exposure
Negative
- None.
News Market Reaction – MBOT
On the day this news was published, MBOT gained 2.79%, reflecting a moderate positive market reaction. This price movement added approximately $4M to the company's valuation, bringing the market cap to $149.09M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
MBOT fell 6.52% while key peers like KRMD (-5.85%), INFU (-4.63%), NYXH (-4.17%), AVR (-3.39%), and STXS (-3.03%) also traded lower. Despite multiple peers declining, the momentum scanner did not flag a coordinated sector move, suggesting MBOT’s action leaned stock-specific.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 14 | Conference presentation | Positive | +3.4% | Planned Needham conference talk on LIBERTY FMR and growth strategy. |
| Apr 13 | Full market launch | Positive | -9.3% | Announcement of U.S. Full Market Release of LIBERTY at SIR meeting. |
| Mar 26 | Clinical use update | Positive | +3.6% | Emory’s first robotic PAE and Y-90 mapping using LIBERTY system. |
| Mar 24 | Pivotal study publication | Positive | -0.8% | ACCESS-PVI pivotal study publication supporting broader LIBERTY adoption. |
| Mar 17 | Investor conference | Positive | +1.1% | Roth Conference participation to discuss LIBERTY commercialization plans. |
Recent LIBERTY-related news has generally been positive, with mixed market reactions: three positive moves and two selloffs on good news, indicating occasional profit-taking or dilution concerns around strong updates.
Over the past month, MBOT has consistently highlighted the commercialization of its LIBERTY® Endovascular Robotic System. Key steps included Limited Market Release in late 2025, FDA clearance in September 2025, and recent transition to Full Market Release announced on April 13, 2026. Emory Healthcare’s successful robotic procedures and publication of the ACCESS-PVI pivotal study in March further strengthened clinical validation. Today’s guidelines-focused news continues the theme of emphasizing radiation and ergonomic benefits that underpin LIBERTY’s positioning.
Regulatory & Risk Context
The company has an active shelf registration on Form S-3/A filed on 2025-10-28, which has been used multiple times as indicated by 3 recent prospectus supplements, including a 424B5 on 2026-04-10. While the amendment filing highlights approximately $25,000.00 in issuance and distribution expenses and an SEC fee of $404.02, it does not modify the prospectus terms.
Market Pulse Summary
This announcement reinforces LIBERTY’s positioning around physician safety, highlighting that at least nine medical societies and the AMA have emphasized radiation and ergonomic protection in interventional radiology. It builds on recent milestones such as FDA clearance in September 2025 and the U.S. Full Market Release in April 2026. Investors may watch how quickly guideline awareness translates into hospital adoption and procedure volume, while also monitoring further use of the active ATM program and related filings for potential dilution.
Key Terms
interventional radiology medical
endovascular medical
ionizing radiation medical
endovascular robotic system technical
radiation protection medical
musculoskeletal medical
occupational radiation exposure medical
AI-generated analysis. Not financial advice.
Members of the Society of Interventional Radiology (SIR) and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Represent the Largest Addressable User Market for the LIBERTY System
At least Nine Medical Societies Endorse Updated Guidelines to Lower Radiation Exposure and Improve Ergonomic Issues Impacting Health Practitioners
HINGHAM, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, today highlighted that the Society of Interventional Radiology (SIR) and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE), recently released updated joint guidelines on occupational protection in interventional radiology. The revised guideline provides important safety guidance to physicians, radiographers, nurses, medical physics experts, and all other staff involved in interventional radiology procedures.
The guidelines, which were published in CardioVascular and Interventional Radiology (CVIR), cover updated clinical evidence, new exposure sources and address musculoskeletal risks for interventional radiology staff and, for the first time, include a section on radiation protection during pregnancy for female practitioners.
“Part of our mission for the LIBERTY System is to enable physicians to continue improving and saving patients’ lives while protecting their own. LIBERTY’s design aims to reduce radiation exposure and physical strain for physicians and related medical staff, positioning the LIBERTY System as a potential solution to address both the health, and the staffing challenges in interventional care,” commented Harel Gadot, Chairman, CEO & President. “It is very encouraging to see increased emphasis on protecting healthcare providers in the interventional space coming from leading medical societies, such as the American Medical Association (AMA), one of the largest medical associations in the U.S., along with SIR and CIRSE.”
Prolonged exposure to radiation may have significant long-term health risks, including cancer, cardiovascular disease, reproductive health effects, and cataracts. These risks have also been cited as contributing to the staffing shortage in the endovascular space, especially in interventional radiology, which currently ranks number two among specialties with highest physician shortages. The burden disproportionately affects women, who often cite radiation exposure and the physical demands of wearing lead aprons as barriers to entering or advancing in the field. The LIBERTY System’s remote operation capabilities enable physicians to work away from the radiation source and in a seated position, potentially lowering musculoskeletal strain while improving workflow efficiency.
Along with SIR and CIRSE, occupational protection initiatives are being endorsed by the Society of NeuroInterventional Surgery (SNIS), the Society of Vascular and Interventional Neurology (SVIN), the Society for Cardiovascular Angiography and Interventions (SCAI), American College of Cardiology (ACC), the Alliance for Cardiovascular Professionals (ACVP), the American Society of Echocardiography (ASE), the Heart Rhythm Society (HRS), and Society for Vascular Surgery (SVS). Additionally, in late 2025, the American Medical Association (AMA) adopted a new policy to strengthen protections for healthcare professionals and trainees who may face occupational radiation exposure. The policy emphasizes the importance of continued research into the health effects of cumulative exposure to ionizing radiation, as well as education and training to minimize occupational risk to physicians and patients.
About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot’s LIBERTY® Endovascular Robotic System is the world’s first FDA cleared single-use, remotely operated robotic solution designed for precision, efficiency and safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care.
Learn more at www.microbotmedical.com and connect on LinkedIn and X.
Safe Harbor
Statements to future financial and/or operating results, future adoption of products, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,” “intends,” “may,” “might,” “possible,” “potential,” “predicts,” “projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the commercialization of the LIBERTY® Endovascular Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S., disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical® disclaims any intent or obligation to update these forward-looking statements, except as required by law.
Contacts:
IR@microbotmedical.com
Media@microbotmedical.com
